Home » Blog » Kaput Acquisitions, Cancer Drugs and Quality Measures

Kaput Acquisitions, Cancer Drugs and Quality Measures


IP Blog | Dave Melin | February 5, 2017

BioBlog WeeklyThis week’s BioBlog outlines the Anthem Cigna deal,  several articles on increased prices of cancer drugs, and suggestions to improve oncology quality measures.

Anthem’s Cigna Deal Is All but Kaput, and That May Be Good News for Blues Plans

It seems likely that Anthem’s plan to buy Cigna will not be approved, since it would substantially reduce competition in many metropolitan areas.

Europe Faces Steep Price Increases for Some Old Cancer Drugs

Reuters reports that the price of some off-patent cancer drugs have been facing steep price increases in recent years.

As Cancer Drugs’ Prices Skyrocket, Experts Worry About Burden On Patients, Health Systems

In this article from Common Health, industry leaders note that new treatments come with a price tag that many believe is unsustainable.

New Study Outlines Gaps, Offers Strategies to Improve Oncology Quality Measures

National Pharmaceutical Council reports on a new study published in the Journal of Managed Care & Specialty Pharmacy.

Europe Faces Steep Price Increases for Some Old Cancer Drugs

European prices for some off-patent cancer drugs have risen by more than 100 percent in the past five years, with two cases of hikes exceeding 1,000 percent.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *